New bioprosthetic valve for TAVR fails to demonstrate non-inferiority

(Cardiovascular Research Foundation) In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve.